SCN5A and heart failure: Disease processes such as atrial fibrillation and left-sided versus right-sided heart failure affect cardiac cells within specific regions, although current pharmacotherapies for these may not specifically target the affected region-specific cell types, resulting in adverse outcomes (for example, the SCN5A blocker flecainide is used to treat atrial fibrillation but can induce ventricular arrhythmias22).